期刊文献+

盐酸坦索罗辛单药治疗BPH 100例临床疗效观察 被引量:3

Clinical observation on the therapeutic effect of the single therapy by Tamsulosin on 100 cases of benign prostatic hyperplasia
下载PDF
导出
摘要 目的观察坦索罗辛单药治疗BPH(良性前列腺增生症)导致的LUTS(下尿路症状)的临床疗效。方法门诊选择100例BPH患者,随机分成2组,试验组50例,服用盐酸坦索罗辛0.2mg,1次/d;对照组50例,同时服用非那雄胺5.0mg,1次/d,盐酸坦索罗辛0.2mg,1次/d,观察药物治疗效果,主要是下尿路症状的改善。结果 1个月内下尿路症状的有效改善为试验组49例(98%),对照组48例(96%),两组差异无统计学意义(P>0.05)。两组患者IPSS均≤13分,QOL为(3±1)分,Qmax均≤18ml/s,残余尿量测定均≤40ml,服药前后比较并有统计学意义(P≤0.05)。结论盐酸坦索罗辛单药治疗BPH导致的LUTS的临床疗效满意。 Objective To observe the therapentic effects of Tamsulosin for the treatment of benign prostatic hyperplasia (BPH). Methods 100 outpatients with benign prostatic hyperplasia received were selec- rived, and were randomly divided into two groups. The experimental group ( 50 patients ) given Tamsulosin 0. 2 mg once a day , and the control group(50 patients) received Tamsulosin 0. 2 mg once a day and Finasteride 5 mg once a day both. Observed the efficiency of the drug therapy, mainly the improvement of the lower urinary tract symptoms(LUTS). Results The lower urinary tract symptoms had improved effectively in 1 month, in the experimental group has 49 patients (98%) , and the control group has 48 (96%) , the difference between the ex-perimental group and the control group has no statistical significance( P 〉 0. 05 ). Both Of the two groups, the IPSS ≤13 points, the QOL is 3 ±1 points,Qmax≤18 ml/s, the residual urine volume≤40 ml, the difference has statistical significance(P ≤0. 05 ). Concision The single therapy by Tamsulosin has a satisfactory clinical effect on the the treatment of LUTS caused by BPH.
出处 《中国实用医药》 2010年第19期29-30,共2页 China Practical Medicine
关键词 良性前列腺增生症 下尿路症状 盐酸坦索罗辛 Benign prostatic hyperplasia (BPH) Lower urinary tract symptoms (LUTS) Tamsulosin
  • 相关文献

参考文献4

二级参考文献6

  • 1Gu F L, Xia T L, Kong X T. Preliminary studyof the frequency of benign prostatic byperplasia and prostatic cancer in china[J]. Urology.1991.11(5):688 -691.
  • 2Sarma A V. Burke J P, Jacobson D J, et al. Associa tions between diabetes and clinical markers of benign prostatic hyperplasia among community dwelling black and white men[J]. Diabetes Care. 2008.31 (3) : 476 -- 482.
  • 3Parsons J K. Carter H B. PartinA W, etal. Metabolic factors associated with benign prostatic hyperplasla[J]. Clin Endocrinol Metab.2006,91(7):2562--2568.
  • 4Homma Y. Kawabe K, Tsukamoto T, et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the International Prostate Symptom Score[J]. Int Urol,1997.2:232.
  • 5Yanardag H, Goktas S, Kibar Y. et al. Intermittent tamsulosin therapy in me with lower urinary tract symptoms[J].Journal of Urology, 20(}5. 173(1):155--157.
  • 6刘东明,黄翼然,江鱼,姚德鸿,董国勤,叶敏,张祖豹,金三宝,陈曾德.盐酸坦索罗辛治疗不同体积良性前列腺增生症的疗效观察[J].临床泌尿外科杂志,1999,14(7):287-290. 被引量:10

共引文献6

同被引文献34

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部